IP Library Granted Patent US 10,130,602
Granted Patent B2
US 10,130,602 · App. 14/009,470 · Granted Nov 20, 2018

Use of L-carnitine, salts and derivatives thereof for reducing or preventing fatigue and improving cognitive function

Inventors: Adriana Williams (Riehen, CH); Frauke Warrikoff (Frankfurt, DE); Ulla Freitas (Lorrach, DE); Richard Sasse (Bavel, NL); Kevin Owen (Canyon, TX)
Assignee: Lonza Ltd.
A61K31/205
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,130,602
App. No.
14/009,470
Granted
Nov 20, 2018
Kind
B2
Abstract

The invention relates to the use of L-carnitine, a salt of L-carnitine, a derivative of L-carnitine and/or salt of a derivative of L-carnitine, as well as respective methods and compositions, for reducing or preventing fatigue and/or for improving cognitive function in an animal. The animal is preferably a healthy individual and the use is preferably a non-therapeutic use.

Claims (19)

1. A non-therapeutic method for reducing or preventing mental fatigue and/or for improving cognitive function of a healthy non-elderly individual having an age of from about 16 to about 50 years of age, wherein the mental fatigue and/or impaired cognitive function that is prevented or improved is not the result of a disease or due to old age, the method comprising administering an amount of L-carnitine, and/or a salt of L-carnitine corresponding to an equivalent amount of L-carnitine of from about 100 mg to about 1500 mg to the individual in a single dose over a time period of not more than one day, wherein the L-carnitine, and/or a salt of L-carnitine, is not administered in combination with another agent which is effective in reducing or preventing fatigue or for improving cognitive function of the individual.

2. The method of claim 1 , wherein the animal is human.

3. The method of claim 1 , wherein the animal does not suffer from chronic L-carnitine deficiency.

4. The method of claim 1 , wherein before administration of the L-carnitine,

and/or salt of L-carnitine, the animal is experiencing a temporary fatigue and/or temporary impairment of cognitive function.

5. The method of claim 1 , wherein the salt is a tartrate, citrate, succinate, fumarate or hydrochloride.

6. The method of claim 1 , wherein the L-carnitine, and/or salt of L-carnitine, is administered in an amount corresponding to an equivalent amount of L-carnitine between 250 and 1000 mg.

7. The method of claim 1 , wherein the L-carnitine, and/or salt of L-carnitine, is administered as part of a solid composition comprising more than 50% (w/w) L-carnitine.

8. The method of claim 1 , wherein the L-carnitine, and/or salt of L-carnitine, is administered orally.

9. The method of claim 1 , wherein the animal is a horse or a pet.

10. A method for reducing or preventing mental fatigue and/or for improving cognitive function in a healthy non-elderly animal having an age of from about 16 to about 50 years of age, wherein the mental fatigue and/or impaired cognitive function that is prevented or improved is not the result of a disease or due to old age, comprising administering an amount of L-carnitine and/or a salt of L-carnitine corresponding to an equivalent amount of L-carnitine of from about 100 mg to about 1500 mg, to that animal, wherein the method is non-therapeutic, and wherein the L-carnitine and/or salt of L-carnitine is not administered over a time period of more than one day, and wherein the L-carnitine, and/or a salt of L-carnitine, is not administered in combination with another agent which is effective in reducing or preventing fatigue or for improving cognitive function of the individual.

11. The method of claim 6 , wherein the L-carnitine, and/or salt of L-carnitine, is administered in an amount corresponding to an equivalent amount of L-carnitine between 250 and 1000 mg.

12. The method of claim 8 , wherein the L-carnitine, and/or salt of L-carnitine, is administered in the form of a liquid, a solid preparation, a gel or a paste.

13. The method of claim 12 , wherein the solid preparation is a tablet, capsule or powder.

14. The method of claim 10 , wherein the L-carnitine and/or salt of L-carnitine is administered in response to multiple outbreaks of fatigue or cognitive problems within a relatively short time period.

15. The method for improving cognitive function of claim 10 , wherein short time cognitive function is improved.

16. The method of claim 15 , wherein the short time cognitive function is improved within a time span of 1 to 3 hours after administration.

17. The method of claim 1 , wherein short time cognitive function is improved.

18. The method of claim 17 , wherein the short time cognitive function is improved within a time span of 1 to 3 hours after administration.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 18, 2026
From: LONZA LTD, ALSO KNOWN AS LONZA AG
To: CAPSUGEL SWITZERLAND AG
Reel/Frame 073827/0097 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 19, 2013
From: WILLIAMS, ADRIANA; WARRIKOFF, FRAUKE; FREITAS, ULLA; SASSE, RICHARD; OWEN, KEVIN
To: LONZA LTD.
Reel/Frame 031818/0421 →
Priority Claims (2)
EP 11002833 · Apr 5, 2011 · regional
EP 11003448 · Apr 27, 2011 · regional
Continuity (2)
Provisional Application 61479653 · Apr 27, 2011
Related Publication 20140107201A1 · Apr 17, 2014
Cited By (2)
US 12,208,077 US 12,226,385